

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

NCT07226895

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Monument Therapeutics Limited
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (4)

- Aged 17 to 30 years at time of consent.
- Capacity to provide informed consent. (For patients under 17 years, participants must assent and informed consent provided by one parent or legal guardian).
- Meet diagnostic criteria for Clinical High Risk of Psychosis (CHR).
- For females of reproductive potential - not pregnant or nursing and willing to comply with contraceptive requirements.

Exclusion (8)

- Clinically significant medical disorder or laboratory test abnormality at Day 1.
 - History of or current condition which may prevent participant from complying with study procedures.
 - Past or current schizophrenia, other disorder with symptoms of psychosis, major cognitive disorder resulting from traumatic brain injury.
 - Received antipsychotic medication equivalent to a total lifetime haloperidol dose ≥ 50 mg.
 - Current use of medications which could interfere with the study endpoints - to be assessed by the Investigator at screening.
- ... and 3 more (see full listing online)

Locations (15 total)

University of California, Irvine, Irvine, California, United States
University of California, Los Angeles, California, United States
University of California, San Francisco, San Francisco, California, United States
... and 12 more locations